Uncategorised - European Medical Journal

contract

Dr Dietmar Berger appointed as Gilead’s next Chief Medical Officer

Dr Dietmar Berger is set to join Gilead Sciences as Chief Medical Officer on 2 January 2025 – succeeding Dr Merdad Parsey.

Carrageenan Linked to Insulin Resistance and Inflammation in Overweight Individuals

Carrageenan, a widely used food additive, may worsen insulin resistance and inflammation in overweight individuals, a new study reveals, sparking concerns over its impact on metabolic health.

The Role of Eosinophils in Allergic Asthma

Benralizumab has shown efficacy in reducing asthma exacerbations and controlling symptoms in severe eosinophilic asthma.

Risk-Reducing Surgery for BRCA Carriers: SABCS 2024

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

COMET Trial Suggests Active Monitoring for Low-Risk DCIS: SABCS 2024

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

Melanoma Survivors Face 57% Increased Risk of Malignancies

Survivors of cutaneous melanoma (CM) face a 57% increased risk of developing second primary malignancies (SPMs) compared to the general population, according to groundbreaking research from a recent analysis of SEER database data spanning two decades.

Treg Cells: Helpers or Harmers in Arthritis?

Regulatory T (Treg) cells are vital for immune system balance, preventing autoimmune diseases by suppressing inflammation.

Epilepsy Prevention Using ARBs After Stroke: AES 2024

Stroke survivors with hypertension may have a new ally in reducing their risk of post-stroke epilepsy (PSE): angiotensin receptor blockers (ARBs).

Next-Gen SERD Improves Outcomes in Resistant Breast Cancer: SABCS 2024

At the 2024 San Antonio Breast Cancer Symposium (SABCS), new Phase III trial data presented the promising results of imlunestrant, an oral next-generation selective estrogen receptor degrader (SERD), in patients with advanced breast cancer.

How to Reduce Liver Fat Through Targeted Dietary Interventions

Lifestyle modifications, particularly dietary changes, have shown potential in reversing MASLD and steatohepatitis.